Diabetes drug Actos at heart of record rulingBy
A U.S. federal court seated in Lafayette, La., found the makers of the diabetes drug Actos liable in a lawsuit that claims the manufacturer did not do enough to warn users that the drug greatly increased the risk of developing bladder cancer. Takeda Pharmaceutical Co Ltd said it would contest $6 billion in punitive damages imposed by the jury in the case claiming that Japan’s largest drugmaker had concealed cancer risks associated with Actos. Eli Lilly and Co, Takeda’s co-defendant in the case, was ordered to pay $3 billion in punitive damages.
In June 2011, the U.S. Food and Drug Administration published a drug safety update on Actos, which said there was a 40 percent increase in bladder cancer risk in people who used the drug for longer than a year. It required that the cancer risk be added to the medication’s warning label. Actos has been sold since 1999. Actos comes with warnings about various serious side effects, including liver problems and higher risk of broken bones.
For complete article, see Jury hits Takeda, Eli Lilly with $9-billion penalty